| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (NCT03425461) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) | National Cancer Institute (NCI) | 2018-06-05 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery (NCT03384836) | Roswell Park Cancer Institute | 2018-01-31 |
| Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma (NCT03276832) | Mayo Clinic | 2017-12-20 |
| Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma (NCT03325101) | Mayo Clinic | 2017-11-15 |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer (NCT03050060) | University of Washington | 2017-06-09 |
| Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT03021460) | Mayo Clinic | 2017-01-31 |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma (NCT02581930) | National Cancer Institute (NCI) | 2016-12-16 |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (NCT02910700) | M.D. Anderson Cancer Center | 2016-12-09 |
| Neoadjuvant and Adjuvant Checkpoint Blockade (NCT02519322) | M.D. Anderson Cancer Center | 2016-02-02 |
| A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (NCT02339571) | National Cancer Institute (NCI) | 2015-11-23 |
| Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma (NCT02500576) | M.D. Anderson Cancer Center | 2015-08-07 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (NCT01740557) | M.D. Anderson Cancer Center | 2015-01-28 |
| CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT02027935) | M.D. Anderson Cancer Center | 2015-01-22 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma (NCT01955460) | M.D. Anderson Cancer Center | 2014-10-15 |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (NCT02196181) | National Cancer Institute (NCI) | 2014-09-19 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075) | National Cancer Institute (NCI) | 2014-04-09 |
| Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01950390) | National Cancer Institute (NCI) | 2014-01-24 |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (NCT02158520) | Academic and Community Cancer Research United | 2013-10-18 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (NCT01940809) | National Cancer Institute (NCI) | 2013-08-28 |
| Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma (NCT01807182) | Fred Hutchinson Cancer Center | 2013-08-20 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01708941) | National Cancer Institute (NCI) | 2013-03-25 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer (NCT01727076) | National Cancer Institute (NCI) | 2013-02-15 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (NCT01480154) | National Cancer Institute (NCI) | 2011-11-23 |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (NCT01364051) | National Cancer Institute (NCI) | 2011-05-25 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (NCT01303341) | National Cancer Institute (NCI) | 2011-02-18 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01258855) | National Cancer Institute (NCI) | 2011-01-18 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT01134614) | National Cancer Institute (NCI) | 2010-12-28 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| Dinaciclib in Treating Patients With Stage IV Melanoma (NCT00937937) | National Cancer Institute (NCI) | 2009-07-01 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery (NCT00861913) | National Cancer Institute (NCI) | 2009-04-03 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery (NCT01989572) | National Cancer Institute (NCI) | 2000-02-23 |